Jin Tianqiang, Dai Chaoliu, Xu Feng
Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Department of General Surgery, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, Liaoning Province 110004, China.
Ther Adv Med Oncol. 2020 Jun 23;12:1758835920933034. doi: 10.1177/1758835920933034. eCollection 2020.
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with increasing incidence and mortality. More than half of PDAC patients develop metastases, with the liver being the most common site. Patients with pancreatic ductal adenocarcinoma with liver metastases (PCLM) have a very limited scope for surgery due to aggressive tumor behavior and poor prognosis. However, with the improvements in preoperative systemic therapy and perioperative outcomes, an increasing number of patients are being considered for surgical management. However, the best choice of surgical treatment and criteria for selecting suitable PCLM patients who may benefit from surgical treatment remains controversial. Palliative local treatments, such as ablation, locoregional chemotherapy, and brachytherapy, which are less invasive and have fewer contraindications and complications, are the preferred alternatives to surgery. The present study reviews the advances in the management of PCLM, with focus on resection and local therapies.
胰腺导管腺癌（PDAC）是一种发病率和死亡率不断上升的致命疾病。超过一半的PDAC患者会发生转移，肝脏是最常见的转移部位。由于肿瘤侵袭性强且预后较差，伴有肝转移的胰腺导管腺癌（PCLM）患者的手术范围非常有限。然而，随着术前全身治疗和围手术期治疗效果的改善，越来越多的患者被考虑进行手术治疗。然而，手术治疗的最佳选择以及选择可能从手术治疗中获益的合适PCLM患者的标准仍存在争议。姑息性局部治疗，如消融、局部区域化疗和近距离放疗，具有侵入性较小、禁忌证和并发症较少的特点，是手术的首选替代方案。本研究回顾了PCLM治疗的进展，重点是切除术和局部治疗。
